Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-dependent L-type calcium channel subunit beta-4 (CACNB4)
- Target
- CACNB4
- Molecular classification
- Ion channel (auxiliary subunit), Voltage-gated calcium channel auxiliary subunit
01
Overview
Voltage-dependent L-type calcium channel subunit beta-4 is an auxiliary protein encoded by the CACNB4 gene that forms part of the voltage-gated calcium channel complex in excitable cells[1][6][7]. As a beta subunit, it is critical for regulating surface expression, localization, and functional gating of the calcium channel, especially for high-voltage-activated (L-type and related) channels[2][4]. It modulates channel properties by increasing peak current, shifting activation/inactivation voltages, and enabling G protein modulation of calcium influx—a key process in excitation–contraction coupling, neurotransmitter release, and various neuronal signaling pathways[2][7]. Pathogenic variants contribute to epilepsy subtypes, notably idiopathic generalized and juvenile myoclonic epilepsy[1]. While no approved drugs specifically target this subunit alone, it is essential for physiological calcium channel function and is an important focus in basic neuroscience and channelopathy research.
- Other names
- CACNB4Calcium channel, voltage-dependent, beta 4 subunitVoltage-gated calcium channel subunit beta-4
02
Mechanism of action
Modulation of channel open probability, voltage-dependence, and kinetics for drugs targeting the calcium channel complex[2][5]
03
Biological functions
Modulation of calcium channel activityRegulation of calcium influx into cellsModulation of G protein inhibitionControl of alpha-1 subunit membrane targetingShifting voltage dependence of activation and inactivation
04
Disease associations
EpilepsyIdiopathic generalized epilepsyJuvenile myoclonic epilepsyNeurodevelopmental and neurodegenerative diseases (by association)
05
Safety considerations
Dysfunction/mutation can result in neurological disorders such as epilepsy[1][6]Targeting auxiliary subunits may risk perturbing essential calcium signaling in multiple tissues, causing off-target effects
06
Interacting drugs
No drugs directly target the beta-4 subunit clinically; however, drugs targeting L-type calcium channels as a whole (e.g., dihydropyridines like amlodipine or verapamil) modulate the overall channel function, which includes the beta-4 subunit[5][7]
07
Biomarkers
Mutations in CACNB4 are associated with epilepsy subtypes, making genetic variation a potential biomarker for susceptibility[1]
Beyond the preview
Go deeper on Voltage-dependent L-type calcium channel subunit beta-4 (CACNB4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Voltage-dependent L-type calcium channel subunit beta-4 (CACNB4).